Business Parks & Science Centres

 
 
 

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Evonetix Ltd.. (10/1/18). "Press Release: Evonetix Partner with LioniX International to Enable DNA Synthesis at Scale". Cambridge & Enschede.

Organisations Organisation Evonetix Ltd.
  Organisation 2 LioniX International B.V.
  Group Magic Micro (Group)
Product Product  MEMS (Micro Electro Mechanical System)
Index term Index term Evonetix–Magic Micro: DNA synthesis technology, 201810– collab developm of MEMS for DNA synthesis with LioniX Intl
Person Person Ricketts, Michelle (Zyme Communications 201708– Account Manager before Axol Bioscience)
     


> Collaboration will focus on the development of a bespoke silicon array to enable highthroughput production of high-fidelity gene-length DNA

> DNA synthesis at this level will allow applications in the rapidly growing field of synthetic biology to become a reality


EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and highfidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, will collaborate to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis. LioniX International will use common silicon processing techniques and materials to manufacture a novel thermally addressable silicon array, which will enable Evonetix to control de novo DNA synthesis using its unique synergistic thermal control chemistry to deliver high-throughput assembly of high-fidelity gene-length DNA at scale.

LioniX International will use semiconductor microfabrication techniques to manufacture the thermally addressable silicon array, capable of independent thermal control of multiple reaction sites. Evonetix will use this array to control a synergistic synthesis chemistry, optimised to have reaction rates that are highly dependent on temperature, at each of the 10,000 miniaturised reaction sites, allowing for massive parallelism in the DNA synthesis process and therefore a very high throughput.

Dr Matthew Hayes, Chief Technology Officer at Evonetix, said: “We are excited to be working with LioniX International to develop our silicon array that will be a crucial enabler of Evonetix’s revolutionary DNA synthesis technology. Most existing technologies physically isolate the different oligonucleotides during synthesis in a well. In contrast, our array operates in a continuous flow of liquid with virtual wells made by independently controlled temperature islands. The extremely low effective volume of these virtual wells minimises reagent consumption and therefore cost, whilst the flexibility afforded by the lack of physical boundaries enables innovative synthesis and assembly processes, which are ultimately the key to our ability to synthesise long DNA fragments.”

Bi-directional heat control will ensure a continuous flow of heat within the liquid and deliver the steep temperature gradients that localise the virtual wells. This will be provided via the use of resistive heaters that pump heat into the liquid and a cooled substrate that removes heat through a thermal insulator with controlled thermal resistance.

Dr Andrew Ferguson, Head of Physics at Evonetix, said: “The key innovation in this approach is the realisation of a thermal insulator that provides a controlled, anisotropic thermal resistance. We have engineered a novel structured material that achieves this and can be manufactured by LioniX International using a modified MEMs process.”

Albert Prak, Group Leader MEMs at LioniX International, said: “We’re delighted to be working with Evonetix to develop this technology and have been able to use our MEMs and microfluidic processing expertise to realise a demanding and innovative design. We have been able to assist Evonetix with both process design and prototype manufacture.”

For further information about Evonetix gene synthesis platform: https://www.evonetix.com/technology/ For further information about LioniX International’s customised microsystem solutions: https://www.lionix-international.com/


ENDS


Photos: For high-resolution images please contact michelle.ricketts@zymecommunications.com
Dr Matthew Hayes
Chief Technology Officer Evonetix
Dr Andrew Ferguson
Head of Physics Evonetix
Albert Prak
Group Leader MEMs LioniX International
Evonetix’s thermally addressable silicon array


For further information, please contact:

Matthew Hayes
Evonetix Ltd
Tel: +44 1223 930308
E-mail: matthew.hayes@evonetix.com

Arne Leinse
LioniX International
Tel: +31 53 20 30 053
E-mail: a.leinse@lionix-int.com

Michelle Ricketts
Zyme Communications
Tel: +44 778 9053885
E-mail: michelle.ricketts@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.


Notes to Editors


About Evonetix Ltd

Evonetix is revolutionising gene synthesis with the aim of producing DNA at scale to enable many applications in the rapidly growing field of synthetic biology, across a wide range of industries, from pharmaceuticals to industrial biotech, specialty chemicals, renewables, bioremediation, agriculture and potentially also digital data storage.

The Company’s platform is based upon a novel silicon array and unique synergistic thermal control chemistry, capable of synthesising oligonucleotides in parallel, at each of the 10,000 miniaturised reaction sites. The technology is compatible with both chemical and enzymatic gene synthesis and allows for exquisite control at each site of synthesis. It uses a process of error detection throughout assembly to yield high-fidelity long DNA molecules, including challenging sequences with high-GC content or repeats. Thus, Evonetix’s approach permits massive parallelism in de novo DNA synthesis and enables high-throughput on-chip assembly of high-fidelity gene-length DNA at scale.

Evonetix is based in Cambridge, UK and was founded in 2015 by Cambridge Consultants Ltd and Providence Investment Company Limited. The Company raised £9 million in a series A financing, co-led by DCVC and Draper Esprit, and has been awarded Innovate UK co-funding for a £1.3 million gene synthesis project.

For further information see www.evonetix.com


About LioniX International

LioniX International is a leading global provider of customized microsystem solutions in scalable production volumes. We provide customized solutions for OEM’s and System Integrators, from design to fully assembled modules, by vertical integration and in scalable production volumes. We maintain our technology leadership secured by a strong IP position.

LioniX International develops customized MEMS solutions and produces them in small to medium volumes. We offer flexibility in design as well as in process. We are prepared to leave the standard processing routes and develop customized process variations and combinations to achieve manufacturable solutions meeting your specification requirements.

Our customer base consists of OEM’s, system integrators and startups looking for a MEMS solution. Our MEMS activities are driven by state of the art technology and as such our customers are within the MEMS hot areas, such as bioMEMS, Microfluidics, Physical and Chemical Sensors, and Optofluidics.

Our chips drive your business
www.lionix-international.com


About synthetic biology

With the huge increase in DNA sequence information available to mankind over the past ten years, there now exists an unprecedented opportunity to, for example, engineer metabolic pathways and organisms, improve industrial processes, create new processes and engineer genomes with new or improved traits. This opportunity, known as synthetic biology, is estimated to grow rapidly over the coming years, reaching $40 billion in value in the mid-2020s. Synthetic biology will have a massive impact across many industries and will be fundamental to helping us manage the Earth’s resources.

However, only a highly disruptive technology is likely to achieve the significant improvements in DNA synthesis required to enable and facilitate these opportunities. Evonetix believes that, by providing high-fidelity DNA at scale, without the need for post-synthesis error correction, it will be well placed to capture a significant part of the growing multibillion-dollar synthetic biology opportunity.

   
Record changed: 2018-10-08

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Evonetix Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top